RAPT Therapeutics (NASDAQ:RAPT) reported quarterly losses of $(0.63) per share. This is unchanged from the same period last year.
Tesla Stock On Free Fall Ahead Of Crucial Q1 Earnings: Here Are Key Levels To Watch
The Elon Musk-led company has been struggling with slowing sales volume, and efforts to boost sales have squeezed margins.